Statins and Mortality in Connective Tissue Diseases: Should We Resume the Cardio-rheumatology Spirit in Our Clinics?

REFERENCES

1. 1.↵
   1. Seidel D

   . [Risk factors of arteriosclerosis. Differential profile—various mechanisms?] [Article in German]Z Kardiol 1993;82 Suppl 5:33–7.

   OpenUrlPubMed
2. 2.↵
   1. Anitschkow N

   . [About changes in rabbit aorta in experimental cholesterol steatosis]. [Article in German] Beitr Pathol Anat 1913;56:379–404.

   OpenUrl
3. 3.↵
   1. Brown MS,
   2. Goldstein JL

   . A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34–47.

   OpenUrlFREE Full Text
4. 4.↵
   1. Endo A

   . [111th scientific meeting of the Japanese Society of Internal Medicine: Panel discussion: Internal medicine creating future health care: 2. A lesson from the development of statin drugs]. [Article in Japanese] Nihon Naika Gakkai Zasshi 2014;103:2200–6.

   OpenUrl
5. 5.↵
   1. Boland AJ,
   2. Gangadharan N,
   3. Kavanagh P,
   4. Hemeryck L,
   5. Kieran J,
   6. Barry M,
   7. et al.

   Simvastatin suppresses interleukin Iβ release in human peripheral blood mononuclear cells stimulated with cholesterol crystals. J Cardiovasc Pharmacol Ther 2018;1:1074248418776261.

   OpenUrl
6. 6.↵
   1. Soulaidopoulos S,
   2. Nikiphorou E,
   3. Dimitroulas T,
   4. Kitas GD

   . The role of statins in disease modification and cardiovascular risk in rheumatoid arthritis. Front Med 2018;5:24.

   OpenUrl
7. 7.↵
   1. Zeiser S

   . Immune modulatory effects of statins. Immunology 2018;154:69–75.

   OpenUrl
8. 8.↵
   1. Mason JC,
   2. Libby P

   . Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015;36:482–9.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Prasad M,
   2. Hermann J,
   3. Gabriel SE,
   4. Weyand CM,
   5. Mulvagh S,
   6. Mankad R,
   7. et al.

   Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015;12:168–76.

   OpenUrlPubMed
10. 10.↵
    1. D’Agostino RB,
    2. Vasan RS,
    3. Pencina MJ,
    4. Wolf PA,
    5. Cobain M,
    6. Massaro JM,
    7. et al.

    General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–53.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Agca R,
    2. Heslinga SC,
    3. Rollefstad S,
    4. Heslinga M,
    5. McInnes IB,
    6. Peters MJ,
    7. et al.

    EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Ferraccioli GF,
    2. Gremese E

    . Autoantibodies and thrombophilia in RA: TNFa and TNFa blockers. Ann Rheum Dis 2004;63:613–5.

    OpenUrlFREE Full Text
13. 13.↵
    1. Ferraccioli G,
    2. Alivernini S,
    3. Tolusso B,
    4. Gremese E

    . Should rheumatoid factor (RF) (and antinuclear antibodies (ANA)) become routinary screening test for morbidities in the general population?: From the concept of “benign autoimmunity” to the concept of “autoimmunity as a red flag in preventive medicine”? Autoimmun Rev 2018;17:636–8.

    OpenUrl
14. 14.↵
    1. Jorge A,
    2. Lu N,
    3. Keller S,
    4. Rai SK,
    5. Zhang Y,
    6. Choi HK

    . The effect of statin use on mortality in systemic autoimmune rheumatic diseases. J Rheumatol 2018;45:1689–95.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Blak BT,
    2. Thompson M,
    3. Dattani H,
    4. Bourke A

    . Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251–5.

    OpenUrlPubMed
16. 16.↵
    1. Mammen AL,
    2. Chung T,
    3. Christopher-Stine L,
    4. Rosen P,
    5. Rosen A,
    6. Doering KR,
    7. et al.

    Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713–21.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Piepoli MF,
    2. Hoes AW,
    3. Agewall S,
    4. Albus C,
    5. Brotons C,
    6. Catapano AL,
    7. et al.

    2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016;37:2315–81.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Jacobson TA,
    2. Ito MK,
    3. Maki KC,
    4. Orringer CE,
    5. Bays HE,
    6. Jones PH,
    7. et al.

    National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 2015;9:129–69.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Wanner C,
    2. Tonelli M;
    3. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members

    . KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014;85:1303–9.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Tibrewala A,
    2. Jivan A,
    3. Oetgen WJ,
    4. Stone NJ

    . A comparative analysis of current lipid treatment guidelines: nothing stands still. JACC 2018;71:e45–51.

    OpenUrl